CTC (circulating tumor cells), ctDNA (circulating tumor DNA) and Exosome (exosomes) are known as the liquid biopsy "troika", among which CTC is highly regarded for its unique role in early tumor screening and precision treatment. focus on. In terms of clinical application, CTCs play an important role in early diagnosis, evaluating efficacy and judging prognosis, opening up a new horizon for the diagnosis and treatment of tumors. Therefore, capturing CTCs in blood for detection and analysis has very important clinical significance. In the early stages of tumors, is difficult to observe and judge by conventional means, so CTC liquid biopsy has become one of the ways to assist diagnosis.
At the same time, with the development of multi-omics technology, we have transformed from the single-dimensional information obtained from single-omics to obtaining a multi-dimensional understanding of tumors through multi-omics combination. Combining multi-omics and Liquid biopsy, What is the future transformation and development trend of CTC in clinical application? What is the progress of CTC research in the field of early cancer? Can CTC occupy a place in multidisciplinary joint diagnosis?
At that time, many big names will gather together to discuss the cutting-edge technologies and applications of multi-omics and CTC liquid biopsy.
Forum Highlights Highlights 1: The latest research progress and clinical applications of CTC in the field of early tumor screening
Highlights 2: The combination of multidisciplinary diagnosis, non-biological magnetic separation technology and other cutting-edge fields with CTC liquid biopsy
Highlight 3: Big names face each other at a round table to discuss "Opportunities and challenges of multi-omics and CTC technology in early tumor screening"
ZAODX World Conference on Early Cancer Screening
Time: July 15th-17th
Location: Chimelong International Convention and Exhibition Center, Guangzhou, China
